Delcath Systems Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
37.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$103.2Mnext fiscal year
Monitoring Framework
Key Performance Indicators
Number of active treatment centers Quarterly29Target: 40 active treatment centers by the end of 2026
Rate of new patient starts per site per month Monthly70.0%Target: 75 or higher%
Average number of treatments per patient Quarterly4Target: Consistent at approximately 4 cycles
Total Revenue Quarterly25MTarget: At least $100 million for fiscal year 2026
Watch Items
- Seasonal scheduling challenges and reliance on single trained treatment teamsTrigger: Slowing of new patient starts or volume growth below 20% in Q3/Q4Action: Mitigation efforts by the expanded commercial team and regional managers to optimize scheduling
- Clinical trial site activation for metastatic colorectal cancer programTrigger: Fewer than 26 active trial sites by year-end 2026Action: Accelerate clinical team support and investigator engagement to meet the target
- Clinical trial site activation for metastatic breast cancer programTrigger: Fewer than 15 active trial sites by late 2026Action: Expedite regulatory and administrative approvals at targeted clinical centers
Research as of 19 Jun 2026